Literature DB >> 7525093

Essential drugs for cancer chemotherapy. WHO consultation.

.   

Abstract

The WHO recommendation on essential drugs for cancer chemotherapy has been updated. General principles on the proper role of cancer chemotherapeutic agents in relation to efficacy and on the classification of tumours with respect to their curative potential are discussed. Curable cancers and those cancers where the cost-benefit ratio clearly favours drug treatment can be managed appropriately based on only 24 drugs. Fourteen of them should ideally be available for the treatment of the ten most common cancers, 8 others should be available only where the resources and facilities exist for the treatment of paediatric tumours and leukaemias, and two drugs were recommended for the treatment of tumours for which there is good evidence that systemic treatment will palliate symptoms but not substantially prolong survival. The adoption of these recommendations should result in considerable reduction in both the mortality and morbidity from cancer throughout the world.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525093      PMCID: PMC2486570     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  9 in total

Review 1.  Individualizing dosing of cancer chemotherapy.

Authors:  K Kobayashi; M J Ratain
Journal:  Semin Oncol       Date:  1993-02       Impact factor: 4.929

Review 2.  Interactions of chemotherapy and radiation.

Authors:  E E Vokes
Journal:  Semin Oncol       Date:  1993-02       Impact factor: 4.929

Review 3.  Therapeutic advances in radiologic treatment of cancer.

Authors:  L W Brady; B Micaily; C T Miyamoto; J I Keit; G B Mieszkalski
Journal:  Cancer       Date:  1993-12-01       Impact factor: 6.860

4.  Results of adjuvant interferon study in WHO melanoma programme.

Authors:  N Cascinelli; R Bufalino; A Morabito; R Mackie
Journal:  Lancet       Date:  1994-04-09       Impact factor: 79.321

Review 5.  The newer purine analogs. Significant therapeutic advance in the management of lymphoid malignancies.

Authors:  A Saven; L D Piro
Journal:  Cancer       Date:  1993-12-01       Impact factor: 6.860

Review 6.  The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).

Authors:  R Pazdur; A P Kudelka; J J Kavanagh; P R Cohen; M N Raber
Journal:  Cancer Treat Rev       Date:  1993-10       Impact factor: 12.111

Review 7.  Accomplishments in surgical adjuvant therapy for large bowel cancer.

Authors:  C G Moertel
Journal:  Cancer       Date:  1992-09-01       Impact factor: 6.860

Review 8.  Prostate cancer. Primary hormonal treatment.

Authors:  L Denis
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

Review 9.  Neoadjuvant therapy in cancer treatment.

Authors:  E L Trimble; R S Ungerleider; J A Abrams; R S Kaplan; E G Feigal; M A Smith; C L Carter; M A Friedman
Journal:  Cancer       Date:  1993-12-01       Impact factor: 6.860

  9 in total
  5 in total

Review 1.  Anti-Cancer Drug Validation: the Contribution of Tissue Engineered Models.

Authors:  Mariana R Carvalho; Daniela Lima; Rui L Reis; Joaquim M Oliveira; Vitor M Correlo
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

Review 2.  Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge.

Authors:  Carlos Rodriguez-Galindo; Paola Friedrich; Patricia Alcasabas; Federico Antillon; Shripad Banavali; Luis Castillo; Trijn Israels; Sima Jeha; Mhammed Harif; Michael J Sullivan; Thuan Chong Quah; Catherine Patte; Ching-Hon Pui; Ronald Barr; Thomas Gross
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

3.  Essential medicines for cancer: WHO recommendations and national priorities.

Authors:  Jane Robertson; Ronald Barr; Lawrence N Shulman; Gilles B Forte; Nicola Magrini
Journal:  Bull World Health Organ       Date:  2016-07-05       Impact factor: 9.408

4.  Are we moving towards a new definition of essential medicines?

Authors:  Marcus M Reidenberg
Journal:  J Pharmacol Pharmacother       Date:  2015 Oct-Dec

Review 5.  Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes.

Authors:  Lawrence N Shulman; Claire M Wagner; Ronald Barr; Gilberto Lopes; Giuseppe Longo; Jane Robertson; Gilles Forte; Julie Torode; Nicola Magrini
Journal:  J Clin Oncol       Date:  2015-11-17       Impact factor: 44.544

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.